Drugs / FLAMOD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06681402 | Apr 2025 → Apr 2026 | pneumonia | French National Institute of Health and Medical Research | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLAMOD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06681402 ↗ |
| Action | Activate | “Toll-like receptor 5 agonist” NCT06681402 ↗ |
| Modality | Protein / enzyme biologic | “FLAMOD (GMP-grade flagellin) inhalation” NCT06681402 ↗ |
| Route | Inhaled | “FLAMOD (GMP-grade flagellin) inhalation” NCT06681402 ↗ |
| Target | TLR5 | “Toll-like receptor 5 agonist” NCT06681402 ↗ |